In a recent report, Zacks Small-Cap Research (Zacks SCR) has made the case for its $30 per share target price for Achieve Life Sciences, which is seven times the last closing price. Achieve is a micro-cap company developing the world’s first treatment for vaping addiction. Details Zacks SCR values Achieve…